Clinical Trial: NCT05306340
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Genentech, Inc. |
| Information Provided By: | Genentech, Inc. |
| Last Update Posted: | 2026-11-03 |
Study Overview
Brief Summary
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
Official Title
Conditions
Intervention / Treatment
- Drug: Giredestrant
- Drug: Exemestane
- Drug: Fulvestrant
- Drug: Tamoxifen
- Drug: Everolimus
- Drug: LHRH Agonist
- Drug: Dexamethasone Mouth Rinse
Other Study ID Numbers
- ML43171
- 2022-000199-20
- 2023-506821-12-00
- 2023
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Genentech, Inc. |
| Information Provided By: | Genentech, Inc. |
| Last Update Posted: | 2026-11-03 |
Study Overview
Brief Summary
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
Official Title
Conditions
Intervention / Treatment
- Drug: Giredestrant
- Drug: Exemestane
- Drug: Fulvestrant
- Drug: Tamoxifen
- Drug: Everolimus
- Drug: LHRH Agonist
- Drug: Dexamethasone Mouth Rinse
Other Study ID Numbers
- ML43171
- 2022-000199-20
- 2023-506821-12-00
- 2023